Compare · CORT vs MTRI
CORT vs MTRI
Side-by-side comparison of Corcept Therapeutics Incorporated (CORT) and Mentari Therapeutics Inc. (MTRI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CORT and MTRI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- CORT is the larger of the two at $7.98B, about 8.1x MTRI ($982.3M).
- MTRI has been more active in the news (18 items in the past 4 weeks vs 9 for CORT).
- CORT has more recent analyst coverage (17 ratings vs 0 for MTRI).
- Company
- Corcept Therapeutics Incorporated
- Mentari Therapeutics Inc.
- Price
- -
- -
- Market cap
- $7.98B
- $982.3M
- 1M return
- -
- +36.94%
- 1Y return
- -
- +3.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- News (4w)
- 9
- 18
- Recent ratings
- 17
- 0
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Mentari Therapeutics Inc.
The Company is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The Company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Latest CORT
- Director Swisher Daniel N Jr exercised 1,500 shares at a strike of $13.13 and sold $111,105 worth of shares (1,500 units at $74.07) as part of a pre-agreed trading plan (SEC Form 4)
- Maduck Sean exercised 25,000 shares at a strike of $8.27 and sold $2,046,351 worth of shares (25,000 units at $81.85) as part of a pre-agreed trading plan (SEC Form 4)
- President, Oncology Vieira Roberto Wandenkolk exercised 8,333 shares at a strike of $21.63 and sold $674,069 worth of shares (8,333 units at $80.89) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
- 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
- Director Wilson James N sold $1,148,083 worth of shares (10,000 units at $114.81) as part of a pre-agreed trading plan (SEC Form 4)
Latest MTRI
- SEC Form SCHEDULE 13G filed by Mentari Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Mentari Therapeutics Inc.
- SEC Form SCHEDULE 13D filed by Mentari Therapeutics Inc.
- Officer Seurer Jerad G. was granted 257,000 stock options (SEC Form 4)
- Director Pernice Michelle Patricia was granted 37,000 stock options (SEC Form 4)
- Officer Divis Gregory J was granted 1,560,599 stock options (SEC Form 4)
- Director Bruno Julianne was granted 37,000 stock options (SEC Form 4)
- Officer Hagen Brett R was granted 171,000 stock options (SEC Form 4)
- Director Sandler Laura Lee was granted 37,000 stock options (SEC Form 4)
- Director Shegog Todd was granted 37,000 stock options (SEC Form 4)